Noscira has received US Food and Drug Administration (FDA) fast-track designation for tideglusib (Zentylor) for the treatment of progressive supranuclear palsy, a degenerative brain disorder.
Noscira began Phase II trials of tideglusib in December 2009.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Noscira CEO Belén Sopesén said that fast-track status was an incentive to continue the clinical development of tideglusib for progressive supranuclear palsy, which currently has no treatment options.
The designation is granted to facilitate the development and expedite the review of drugs that treat potentially fatal diseases and meet unmet clinical needs.
Progressive supranuclear palsy affects around five in every 100,000 people.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
